Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients.
Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, Doki N, Fukuda T, Ozawa Y, Katayama Y, Kanda Y, Fukushima K, Matsuoka KI, Takada S, Sawa M, Ashida T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Jo T, et al. Among authors: hirabayashi s. Cytotherapy. 2022 Oct;24(10):1013-1025. doi: 10.1016/j.jcyt.2022.05.009. Epub 2022 Jun 18. Cytotherapy. 2022. PMID: 35729020 Free article.
The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
Tachibana T, Najima Y, Akahoshi Y, Hirabayashi S, Harada K, Doki N, Uchida N, Fukuda T, Sawa M, Ogata M, Takada S, Tanaka M, Matsuhashi Y, Tanaka J, Onizuka M, Ichinohe T, Atsuta Y, Kako S; Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Tachibana T, et al. Among authors: hirabayashi s. Ann Hematol. 2020 Oct;99(10):2393-2404. doi: 10.1007/s00277-020-04212-1. Epub 2020 Aug 15. Ann Hematol. 2020. PMID: 32803312
Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors.
Morishima S, Fukuda T, Doki N, Mori T, Onizuka M, Kawakita T, Kato C, Ozawa Y, Tanaka M, Kurokawa M, Kamimura T, Inoue M, Tanaka J, Ichinohe T, Atsuta Y, Morishima Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Morishima S, et al. Bone Marrow Transplant. 2021 Mar;56(3):646-654. doi: 10.1038/s41409-020-01070-3. Epub 2020 Oct 9. Bone Marrow Transplant. 2021. PMID: 33037403
Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.
Nishiwaki S, Akahoshi Y, Mizuta S, Shinohara A, Hirabayashi S, Noguchi Y, Fukuda T, Uchida N, Tanaka M, Onizuka M, Ozawa Y, Ota S, Shiratori S, Onishi Y, Kanda Y, Sawa M, Tanaka J, Atsuta Y, Kako S. Nishiwaki S, et al. Among authors: hirabayashi s. Blood Adv. 2021 Jan 26;5(2):584-592. doi: 10.1182/bloodadvances.2020003536. Blood Adv. 2021. PMID: 33496752 Free PMC article.
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M. Shimomura Y, et al. Among authors: hirabayashi s. Bone Marrow Transplant. 2021 Sep;56(9):2302-2304. doi: 10.1038/s41409-021-01380-0. Epub 2021 Jun 21. Bone Marrow Transplant. 2021. PMID: 34155357 No abstract available.
Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type.
Konuma T, Kanda J, Kuwatsuka Y, Yanada M, Kondo T, Hirabayashi S, Kako S, Akahoshi Y, Uchida N, Doki N, Ozawa Y, Tanaka M, Eto T, Sawa M, Yoshioka S, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Kimura F. Konuma T, et al. Among authors: hirabayashi s. Clin Cancer Res. 2021 Sep 1;27(17):4825-4835. doi: 10.1158/1078-0432.CCR-20-4856. Epub 2021 Jun 22. Clin Cancer Res. 2021. PMID: 34158357
Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
Nakamura M, Arai Y, Hirabayashi S, Kondo T, Doki N, Uchida N, Fukuda T, Ozawa Y, Tanaka M, Sawa M, Katayama Y, Kanda Y, Shiratori S, Nakamae H, Yoshioka S, Onizuka M, Ichinohe T, Atsuta Y, Kako S. Nakamura M, et al. Among authors: hirabayashi s. Br J Haematol. 2021 Jul;194(2):403-413. doi: 10.1111/bjh.17646. Epub 2021 Jun 22. Br J Haematol. 2021. PMID: 34159580 Free article.
The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
Yanada M, Konuma T, Yamasaki S, Mizuno S, Hirabayashi S, Nishiwaki S, Uchida N, Doki N, Tanaka M, Ozawa Y, Sawa M, Eto T, Kawakita T, Ota S, Fukuda T, Onizuka M, Kimura T, Atsuta Y, Kako S, Yano S. Yanada M, et al. Among authors: hirabayashi s. Ann Hematol. 2021 Dec;100(12):3017-3027. doi: 10.1007/s00277-021-04661-2. Epub 2021 Sep 3. Ann Hematol. 2021. PMID: 34477952
384 results